Quantcast

Latest Lorcaserin Stories

2014-08-01 04:22:02

-- Conference Call and Webcast Scheduled for Today at 8:30 a.m. Eastern Time -- SAN DIEGO, Aug. 1, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2014. "We have continued to see encouraging advancements in the US commercialization of BELVIQ, including a 43% quarter-over-quarter increase in estimated total prescriptions and estimated total per week prescriptions surpassing...

2014-07-30 08:32:46

WOODCLIFF LAKE, N.J. and SAN DIEGO, July 30, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that an article based on post-hoc analyses from the three pivotal Phase 3 trials of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise as a Predictor of Week 52 Weight-Loss Outcomes," was recently published in the online issue of Obesity, the official peer reviewed journal of The Obesity Society. The objective of these...

2014-07-29 08:32:10

-- 2014 Nomination follows Previous Nomination in 2013 -- WOODCLIFF LAKE, N.J. and SAN DIEGO, July 29, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that BELVIQ(®) (lorcaserin HCl) has been nominated by the Galien Foundation and Awards Committee for the 2014 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ was previously nominated for this award in 2013. "Eisai's commitment to patient care is the driving force behind our...

2014-07-25 08:25:54

SAN DIEGO, July 25, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will provide a corporate update and report second quarter 2014 financial results before the NASDAQ Global Select Market opens on Friday, August 1, 2014. That same day, Arena will host a conference call and webcast at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for...

2014-07-10 08:27:50

-- Sales Force Increased to Approximately 600 Sales Specialists -- SAN DIEGO, July 10, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600. Eisai expects this expansion of the sales force will enable them to increase their reach to approximately 92,000 physicians in...

2014-06-09 08:28:41

WOODCLIFF LAKE, N.J. and SAN DIEGO, Calif., June 9, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ(®) (lorcaserin HCl) CIV will be presented at the American Diabetes Association's (ADA) 74th Scientific Sessions taking place June 13-17, 2014 in San Francisco, California. http://photos.prnewswire.com/prnvar/20120413/MM87168LOGO "Eisai is committed to advancing knowledge about the...

2014-05-12 16:28:57

-- Conference Call and Webcast Scheduled for Today at 5:00 p.m. Eastern Time -- SAN DIEGO, May 12, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2014. "We are off to a productive start in 2014 with significant new marketing initiatives for BELVIQ® for chronic weight management, the advancement of our lorcaserin life-cycle management programs and the development of our...

2014-05-09 08:26:05

-- Expansion to Approximately 600 Sales Specialists Follows Initiation of National Television Advertising Campaign -- SAN DIEGO, May 9, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai plans to add more than 200 new contract sales representatives to its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600, triple the size from the commercial launch of BELVIQ in June 2013. Eisai expects this expansion of the sales...

2014-05-09 08:25:56

Expansion Enables Eisai to Reach 90,000 Healthcare Providers WOODCLIFF LAKE, N.J., May 9, 2014 /PRNewswire/ -- Eisai Inc. announced today it will add more than 200 new contract sales representatives to its Metabolic Business Unit, bringing the total sales force for BELVIQ(®) to approximately 600, triple the size from when the FDA-approved prescription therapy for chronic weight management became available in June 2013. This expansion, which becomes effective on July 1, 2014, will allow Eisai...

2014-04-14 12:34:04

SAN DIEGO, April 14, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ® (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. The initial advertisement, which illustrates the struggles that many people face with hunger and body weight, will air on Lifetime, Oxygen, AMC and numerous other networks. BELVIQ is presented as a targeted approach to...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related